Seltorexant
Johnson & Johnson (Janssen) · JNJ-42847922 · MIN-202
FollowEvery change as it happens, and a Monday email
Trials
2 active
26 in total · 1 in the EU
What this is
- How it works
- Orexin-2 receptor antagonist
- Tested for
- Depressive Disorder, Major (2 trials)
- Main trialPhase 3
- “The purpose of this study is to know how well seltorexant works, and also to evaluate safety and maintenance effect of seltorexant compared with placebo as an adjunctive therapy to an antidepressant in improving depressive symptoms in participants with major depressive disorder with insomnia symptoms (MDDIS) who have had an inadequate response to current antidepressant therapy with a selective serotonin reuptake inhibitor (SSRI) or serotonin-norepinephrine reuptake inhibitor (SNRI).”In the company’s words, NCT06559306 on ClinicalTrials.gov
- Other names
- JNJ-42847922 · MIN-202
Other drugs for Depressive Disorder, Major
- AzetukalnerXenon Pharmaceuticals Inc. · Phase 3
- LumateperoneIntra-Cellular Therapies, Inc. · Phase 3
- CYB003Cybin IRL Limited · Phase 3
- Mitizodone PhosphateSunshine Lake Pharma Co., Ltd. · Phase 2/3
- OsavampatorNeurocrine Biosciences · Phase 3
- DT120Definium Therapeutics US, Inc. · Phase 3
Coming up2
- 30 DecPhase 3 trial completes · ClinicalTrials.gov
- 24 Aug 2028Phase 3 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials26
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Recruiting | 30 Dec 2026 | Phase 3 Study of Adjunctive Treatment With Seltorexant in Adult and Elderly Participants With Major Depressive Disorder and Insomnia Symptoms | |
| Phase 3Recruiting | 24 Aug 2028 | A Study of Seltorexant as Monotherapy in Adults and Elderly Participants With Major Depressive Disorder | |
| Phase 3Terminated | 24 May 2022 | A Study of Seltorexant as Adjunctive Therapy to Antidepressants in Adult and Elderly Participants With Major Depressive Disorder With Insomnia Symptoms Who Have Responded Inadequately to Antidepressant Therapy | |
| Phase 3Completed | 25 Apr 2023 | A Study of Seltorexant as Adjunctive Therapy to Antidepressants in Adult and Elderly Participants With Major Depressive Disorder With Insomnia Symptoms Who Have Responded Inadequately to Antidepressant and Long-term Safety Extension Treatment With Seltorexant | |
| Phase 3Completed | 3 Oct 2023 | A Study of Seltorexant Compared to Quetiapine XR as Adjunctive Therapy to Antidepressants in Adult and Elderly Participants With Major Depressive Disorder With Insomnia Symptoms Who Have Responded Inadequately to Antidepressant Therapy | |
| Phase 2Completed | 2 Dec 2015 | Study to Evaluate Efficacy, Safety and Tolerability of JNJ-42847922 in Participants With Insomnia Disorder Without Psychiatric Comorbidity | |
| Phase 2Completed | 12 Jan 2019 | A Study to Evaluate the Efficacy and Safety of JNJ-42847922 as Adjunctive Therapy to Antidepressants in Adult Participants With Major Depressive Disorder Who Have Responded Inadequately to Antidepressant Therapy | |
| Phase 2Completed | 3 Apr 2019 | A Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-42847922 in Participants With Insomnia Disorder | |
| Phase 2Completed | 13 Jun 2019 | A Study to Compare the Efficacy, Safety, and Tolerability of JNJ-42847922 Versus Quetiapine Extended-Release as Adjunctive Therapy to Antidepressants in Adult Participants With Major Depressive Disorder Who Have Responded Inadequately to Antidepressant Therapy | |
| Phase 2Completed | 10 Nov 2023 | A Study of Seltorexant in Participants With Probable Alzheimer's Disease | |
| Phase 1Completed | Jul 2015 | A Study to Investigate the Effect of Increased Gastric pH on the Oral Bioavailability of the Orexin-2 Receptor Antagonist JNJ-42847922 in Healthy Participants | |
| Phase 1Completed | 4 Jan 2016 | A Safety, Efficacy and Biomarker Study of JNJ-42847922 in Participants With Major Depressive Disorder | |
| Phase 1Completed | Feb 2016 | A Drug Interaction Study in Healthy Participants to Assess the Effect of Rifampin on the Pharmacokinetics of JNJ-42847922 | |
| Phase 1Completed | 24 Nov 2017 | A Study to Evaluate the Effect of Multiple Oral Doses of JNJ-42847922 on the Steady-state Pharmacokinetics of an Oral Contraceptive Containing Ethinyl Estradiol and Levonorgestrel in Healthy Female Adult Participants | |
| Phase 1Completed | 30 May 2018 | A Study to Evaluate the Relative Oral Bioavailability of Seltorexant (JNJ-42847922) After Administration of 3 Different Formulations in Healthy Participants Under Fasted and Semi-fasted Conditions | |
| Phase 1Completed | 13 Aug 2018 | A Study to Evaluate the Effects of Single-dose Seltorexant on Electrocardiogram Intervals in Healthy Adult Participants | |
| Phase 1Completed | 29 Apr 2019 | A Study to Investigate the Antidepressant Mechanism-of-action of JNJ-42847922 in Participants With Major Depressive Disorder | |
| Phase 1Completed | 7 Jun 2019 | A Study to Assess the Effect of Seltorexant Compared to Placebo on Respiration During Sleep in Adult Participants With Obstructive Sleep Apnea | |
| Phase 1Completed | 23 Aug 2019 | A Study of Seltorexant (JNJ-42847922) After Single-Dose Administration in Healthy Participants | |
| Phase 1Completed | 20 Dec 2020 | A Study of Seltorexant in Healthy Participants | |
| Phase 1Completed | 19 Nov 2021 | A Study to Evaluate the Effect of Hepatic Impairment on JNJ-42847922 in Adult Participants | |
| Phase 1Completed | 1 Mar 2022 | A Study of JNJ-42847922 (Seltorexant) in Healthy Participants | |
| Phase 1Completed | 18 Oct 2022 | A Study to Evaluate the Effect of Renal Impairment on JNJ-42847922 in Adult Participants | |
| Phase 1Completed | 16 Mar 2023 | A Study of Oral Seltorexant as an add-on Medication to an Antidepressant on On-road Driving Performance in Participants With Major Depressive Disorder | |
| Phase 1Completed | 12 May 2023 | A Study to Determine the Abuse Potential of Seltorexant Compared to Suvorexant and Zolpidem | |
| Phase 1Terminated | 8 Apr 2024 | A Study of Seltorexant as Adjunctive Therapy to Antidepressants in Adolescents With Major Depressive Disorder Who Have an Inadequate Response to Selective Serotonin Reuptake Inhibitor (SSRI) and Psychotherapy |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026